source
- Setara Biosciences raises $90 million to advance rare-disease pipeline after Actio spin-outActio Biosciences shipped its precision epilepsy drug to Jazz Pharmaceuticals and then separated the rest of its genetics-driven pipeline into a new company called Setara Biosciences. Setara has s…
- Acumen scraps sole asset after Alzheimer’s fail, plunging stock 80%Acumen will implement cash-saving strategies and assess its options after sabirnetug failed to beat placebo, leaving the biotech without a clinical program.